Jean Jacques Bienaime - 15 Mar 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
15 Mar 2023
Net transactions value
-$9,106,277
Form type
4
Filing time
17 Mar 2023, 21:22:42 UTC
Previous filing
14 Mar 2023
Next filing
10 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $0 +36,100 +7.4% $0.000000 523,956 15 Mar 2023 Direct F1
transaction BMRN Common Stock Tax liability $828,002 -9,437 -1.8% $87.74 514,519 15 Mar 2023 Direct
transaction BMRN Common Stock Tax liability $8,278,274 -88,623 -17% $93.41 425,896 16 Mar 2023 Direct
holding BMRN Common Stock 247,333 15 Mar 2023 Shares held by Jean-Jacques Bienaime Family Trust
holding BMRN Common Stock 100 15 Mar 2023 Shares held as UTMA custodian for child
holding BMRN Common Stock 100 15 Mar 2023 Shares held as UTMA custodian for child

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Award $0 +49,430 $0.000000 49,430 15 Mar 2023 Common Stock 49,430 $87.74 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units granted on March 15, 2023. Price not applicable.
F2 Option grant vests 12/36th on March 15, 2024 and 1/36th on the 15th day of each month thereafter.